Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access February 13, 2014

Intravascular large B-cell lymphoma with prominent cutaneous manifestation — case report

  • Ewa Stefanko EMAIL logo and Tomasz Wróbel
From the journal Open Medicine


Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of extranodal diffuse large B-cell lymphoma (DLBCL) characterized by selective growth of neoplastic cells within the vascular lumen. IVLBCL involves all types of organs and mostly is associated with poor prognosis, but patients with cutaneous variant have significantly better survival. In this article we report a case of 80-year-old woman with prominent cutaneous manifestation of intravascular large B-cell lymphoma.

[1] Pfleger L, Tappeiner J. On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis?) Hautarzt 1959; 10: 359–363 Search in Google Scholar

[2] Pekic S, Milicevic S, Colovic N, Colovic M and Popovic V. Intravascular large B-cell lymphoma as a cause of hypopituitarism: gradual and late reversal of hypopituitarism after long-term remission of lymphoma with immunochemotherapy. Endocrine 2008; 34: 11–16 in Google Scholar PubMed

[3] Narimatsu H, Morishita Y and Saito S, Shimada K, Ozeki K, Kohno A, Kato Y, Nagasaka T. Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases. Leuk Lymphoma 2004; 45: 1611–1616 in Google Scholar PubMed

[4] Ferreri AJ, Dognini GP and Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalban C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A Pertoldi B, Horvath B, szamor A, Zucca E, Cavalli F. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 2007; 92: 486–492 in Google Scholar PubMed

[5] Roglin J, Boer A. Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin. Br J Dermatol 2007; 157: 16–25 in Google Scholar PubMed

[6] Martusewicz-Boros M, Wiatr E, Radzikowska E, Roszkowski-Sliz K and Langfort R. Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia. J Clin Oncol 2007; 25: 2137–2139 in Google Scholar PubMed

[7] Fukushima A, Okada Y, Tanikawa T, Onaka T, Tanaka A, Higashi T, Tsukada J, Tanaka Y. Primary bilateral adrenal intravascular large B-cell lymphoma associated with adrenal failure. Intern Med 2003; 42: 609–614 in Google Scholar PubMed

[8] Katalinic D, Valkovic T, Lucin K, Rudez J. Intravascular lymphoma and thyroid gland Coll Antropol 2006; 30: 239–241 Search in Google Scholar

[9] Saleh Z, Kurban M, Ghosn S, Awar G, Kibbi AG. Generalized teleangiectasia: a manifestation of intravascular B-cell lymphoma. Dermatology 2008; 217: 318–320 in Google Scholar PubMed

[10] Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, Lopez-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M. Intravascula lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant”. Br J Haematol. 2004; 127: 173–183 in Google Scholar PubMed

[11] Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, Murase T, Pileri SA, Doglioni C, Zucca E, Cavalli F, Nakamura S. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007; 25: 3168–3173 in Google Scholar PubMed

[12] Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma. Arch Dermatol Res. 2009; 301:689–92 in Google Scholar PubMed

[13] Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, Niitsu N, Kosugi H, Tsukamoto N, Miwa H, Asaoku H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Ymaguchi M, Nakamura S, Naoe T, Kinoshita T. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008; 26: 3189–3195 in Google Scholar PubMed

[14] Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalban C, Horvath B, Demeter J, Uziel L, Soffietti R, Seymour JF, Ambrosetti A, Willemze R, Martelli M, Rossi G, Candoni A, De Renzo A, Doglioni C, Zucca E, Cavalli F, Ponzoni M. The addition of rituximab to anthracyclines-based chemotherapy significantly improves outcome in “Western” patients with intravascular large B-cell lymphoma. Br J Haematol 2008; 143: 253–257 in Google Scholar PubMed

[15] Masaki Y, Dong L, Nakajima A, Iwao H, Miki M, Kurose N, Kinoshita E, Nojima T, Sawaki T, Kawanami T, Tanaka M, Shimoyama K, Kim C, Fukutoku M, Kawabata H, Fukushima T, Hirose Y, Takiguchi T, Konda S, Sugai S, Sugai S, Umehara H. Intravascular large B-cell lymphoma proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. Int J Hematol 2009; 89: 600–610 in Google Scholar PubMed

Published Online: 2014-2-13
Published in Print: 2014-4-1

© 2014 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 6.12.2023 from
Scroll to top button